Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report

Clin Lung Cancer. 2024 Sep;25(6):577-580. doi: 10.1016/j.cllc.2024.05.008. Epub 2024 May 25.
No abstract available

Keywords: End stage renal disease (ESRD); MET inhibitor; Mesenchymal-epithelial transition factor; Pharmacokinetics (PK); Severe renal impairment.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / complications
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Exons* / genetics
  • Humans
  • Lung Neoplasms* / complications
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • Male
  • Middle Aged
  • Piperidines
  • Proto-Oncogene Proteins c-met* / genetics
  • Pyridazines
  • Pyridines / therapeutic use
  • Pyrimidines* / therapeutic use
  • Renal Dialysis*
  • Renal Insufficiency / therapy

Substances

  • Proto-Oncogene Proteins c-met
  • tepotinib
  • MET protein, human
  • Pyrimidines
  • Pyridines
  • Antineoplastic Agents
  • Piperidines
  • Pyridazines